# Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

> **NCT05678673** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Exelixis** · enrollment: 317 (actual)

## Conditions studied

- Non-Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** XL092
- **DRUG:** Nivolumab
- **DRUG:** Sunitinib Malate

## Key facts

- **NCT ID:** NCT05678673
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2025-07
- **Final completion:** 2028-06
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05678673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05678673, "Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05678673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*